Please provide your email address to receive an email when new articles are posted on . Hyperimmune intravenous immunoglobulin treatment appeared to significantly increase hemagglutination inhibition ...

Please provide your email address to receive an email when new articles are posted on . New evidence indicates that high neuraminidase inhibition titers better predict protection against influenza and ...

BLUE BELL, Pa., May 16, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its SynCon® avian influenza vaccine generated protective HAI titers against six different ...

Parainfluenza virus type 3 (PIV-3) can cause severe respiratory illness among hematopoietic cell transplantation (HCT) recipients. Factors associated with PIV-3-specific Ab level, and the association ...

BLUE BELL, Pa., Nov. 17, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO), which is advancing synthetic vaccines to fight cancers and infectious diseases, announced today that a ...

Washington, DC, October 26, 2008 - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that an investigational high-dose influenza vaccine demonstrated increased immune ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vaxart, Inc., a privately held, clinical-stage company developing recombinant vaccines that are administered by tablet rather than by injection, today ...

Contrary to our hypothesis, premature infants of 6 to 17 months chronological age did not have lower humoral immune responses to 2 doses of TIV than those of FT infants of similar age. Infants in both ...

If found to be safe and immunogenic, reduced doses of influenza vaccine given by the intradermal route could increase the number of available doses of vaccine. In an open-label study, we randomly ...

• Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said its SynCon avian influenza vaccine generated protective hemagglutination inhibition titers against six different unmatched strains of H5N1 in a ...